Allied Healthcare Group Ltd
Allied Healthcare Group Ltd is a diversified healthcare company focused on Investing in next generation technologies with world class partners, Acquiring strategic assets to grow its product and service offerings and Expanding revenue from its existing medical sales and distribution businesses.
Allied Healthcare Group has assets from Research & Development through to Sales, Marketing and Distribution
- R&D – Lead investment in Coridon, Prof. Ian Frazer’s next generation DNA Vaccine Technology
- Clinical Program – Celxcel, a tissue engineering company that has completed phase 2 human trials for its lead product CardioCel
- Sales, Marketing and Distribution - Rapid growth through acquisition and expansion of the Allied Medical distribution business that has service and product offering across Australia and New Zealand